Nexplanon Generic Name & Formulations
Legal Class
Rx
General Description
Etonogestrel 68mg, barium sulfate 15mg; radiopaque; implantable rod; latex-free; may also contain magnesium stearate.
Pharmacological Class
Progestin.
How Supplied
Single rod implant (in pre-loaded disposable applicator)—1
Manufacturer
Generic Availability
NO
Nexplanon Indications
Indications
Subdermal contraception.
Nexplanon Dosage and Administration
Adult
See full labeling. Insert 1 implant subdermally in the inner side of upper (non-dominant) arm. Remove no later than 3 years after insertion.
Children
Premenarchal: not applicable.
Nexplanon Contraindications
Contraindications
Pregnancy. Thromboembolic disorders. Liver tumors. Active liver disease. Undiagnosed abnormal genital bleeding. Breast or other progestin-sensitive carcinoma.
Nexplanon Boxed Warnings
Not Applicable
Nexplanon Warnings/Precautions
Warnings/Precautions
Complete physical exam before insertion and at least annually. Exclude pregnancy (see full labeling for switching from other contraceptive methods); use back-up contraception if appropriate. Complications of insertion and removal (eg, pain, paresthesias, bleeding, scarring, infection); incomplete or incorrect insertions may lead to expulsion or migration. See full labeling for insertion and removal technique; perform only if properly qualified. Remove implant if jaundice or thrombotic event occurs, or if a pregnancy is maintained; consider removing in prolonged immobilization. Risk of thromboembolism with pregnancy and post delivery; avoid use prior to 21 days postpartum. History of breast cancer; monitor. History of hypertension; monitor closely; remove implant if BP is significantly elevated or uncontrolled. Renal disease. Depression. Monitor diabetes, hyperlipidemia. Conditions aggravated by fluid retention. Risk of in situ broken or bent implant. Overweight women (may be less effective). Nursing mothers: may use after 4th postpartum week.
Nexplanon Pharmacokinetics
See Literature
Nexplanon Interactions
Interactions
May be potentiated by CYP3A4 inhibitors (eg, itraconazole, voriconazole, fluconazole, grapefruit juice, ketoconazole). May be antagonized by certain enzymes including CYP3A4 inducers (eg, efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, St. John's wort-containing products); use non-hormonal contraception or back-up method during and for 28 days after discontinuing the enzyme inducer. May be affected by HIV/HCV protease inhibitors or NNRTIs. May affect plasma levels of cyclosporine (increased) or lamotrigine (decreased). May affect measurement of sex hormone-binding globulin, thyroxine.
Nexplanon Adverse Reactions
Adverse Reactions
Headache, vaginitis, weight increase, acne, mastodynia, abdominal pain (exclude ectopic pregnancy), pharyngitis, leukorrhea, influenza-like symptoms, dizziness, dysmenorrhea, back pain, emotional lability, nausea, pain, nervousness, depression, insertion site pain; menstrual irregularities (eg, amenorrhea, changes in bleeding patterns), thrombotic events, others (see full labeling).
Nexplanon Clinical Trials
See Literature
Nexplanon Note
Notes
Provide adequate counseling. Obtain signed written consent (see full labeling).
Nexplanon Patient Counseling
See Literature
Images
